Investment Bankers Foresee Strong Biopharma M&A Deal Flow In 2026

A Pause After Big Q4, But More Coming This Year

 
• By Mandy Jackson
  
M&A activity ended 2025 on a high note but got off to a slow start in 2026 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business